Avior Wealth Management LLC Sells 192 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Avior Wealth Management LLC trimmed its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 4.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,445 shares of the medical research company’s stock after selling 192 shares during the quarter. Avior Wealth Management LLC’s holdings in Laboratory Co. of America were worth $1,019,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Janney Montgomery Scott LLC grew its position in Laboratory Co. of America by 5.5% during the 4th quarter. Janney Montgomery Scott LLC now owns 33,219 shares of the medical research company’s stock worth $7,618,000 after acquiring an additional 1,723 shares during the last quarter. Daymark Wealth Partners LLC grew its position in Laboratory Co. of America by 0.8% during the 4th quarter. Daymark Wealth Partners LLC now owns 7,995 shares of the medical research company’s stock worth $1,833,000 after acquiring an additional 61 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Laboratory Co. of America by 1.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 30,336 shares of the medical research company’s stock worth $6,957,000 after acquiring an additional 485 shares during the last quarter. Simon Quick Advisors LLC bought a new stake in shares of Laboratory Co. of America in the 4th quarter worth approximately $464,000. Finally, Clear Harbor Asset Management LLC grew its position in shares of Laboratory Co. of America by 1.7% in the 4th quarter. Clear Harbor Asset Management LLC now owns 3,998 shares of the medical research company’s stock worth $917,000 after buying an additional 65 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors.

Insider Transactions at Laboratory Co. of America

In related news, EVP Der Vaart Sandra D. Van sold 1,000 shares of the company’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $239.42, for a total value of $239,420.00. Following the completion of the transaction, the executive vice president now owns 2,670 shares of the company’s stock, valued at approximately $639,251.40. This represents a 27.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Adam H. Schechter sold 6,189 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $243.47, for a total value of $1,506,835.83. Following the sale, the chief executive officer now owns 87,441 shares of the company’s stock, valued at approximately $21,289,260.27. This trade represents a 6.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,572 shares of company stock worth $5,915,209. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Stock Up 0.8 %

LH stock opened at $246.29 on Friday. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $247.99. The business has a fifty day moving average price of $234.75 and a 200-day moving average price of $226.67. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The stock has a market capitalization of $20.60 billion, a P/E ratio of 47.64, a P/E/G ratio of 1.81 and a beta of 1.06.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.02. The business had revenue of $3.28 billion during the quarter, compared to analyst estimates of $3.26 billion. Laboratory Co. of America had a return on equity of 15.27% and a net margin of 3.43%. Laboratory Co. of America’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.38 earnings per share. Equities analysts forecast that Laboratory Co. of America Holdings will post 14.51 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Analyst Ratings Changes

LH has been the topic of a number of recent analyst reports. HSBC upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Wednesday, October 30th. Bank of America lifted their price objective on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Piper Sandler lifted their price target on Laboratory Co. of America from $235.00 to $240.00 and gave the company a “neutral” rating in a research report on Monday, October 28th. Morgan Stanley lifted their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Finally, Robert W. Baird lifted their price target on Laboratory Co. of America from $282.00 to $289.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Laboratory Co. of America has a consensus rating of “Moderate Buy” and an average target price of $260.54.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.